KRAS and non-small cell lung carcinoma: Approvals of immune checkpoint inhibitors [nivolumab (14), pembrolizumab (15), and atezolizumab (16)] changed the standard of care in first-line therapy and after platinum-based treatment failure; however, these agents do not specifically target patients with metastatic KRAS-mutated NSCLC, which continues to be an area of significant unmet medical need.